Y-mAbs Therapeutics, Inc.

YMAB · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$29,666-$21,427-$95,568-$55,275
Dep. & Amort.$535$735$839$782
Deferred Tax$0$0$0$1,897
Stock-Based Comp.$14,559$14,453$25,603$19,334
Change in WC-$3,649-$19,734-$10,371-$7,284
Other Non-Cash$2,507-$1,259$3,576-$62,010
Operating Cash Flow-$15,714-$27,232-$75,921-$102,556
Investing Activities
PP&E Inv.$0$0$0-$967
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$62,010
Investing Cash Flow$0$0$0$61,043
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$4,311$100$84$107,725
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$589
Financing Cash Flow$4,311$100$84$108,314
Forex Effect$0$7$35$129
Net Chg. in Cash-$11,403-$27,125-$75,802$66,930
Supplemental Information
Beg. Cash$78,637$105,762$181,564$114,634
End Cash$67,234$78,637$105,762$181,564
Free Cash Flow-$15,714-$27,232-$75,921-$103,523
Y-mAbs Therapeutics, Inc. (YMAB) Financial Statements & Key Stats | AlphaPilot